Phase 1 N=87 A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Advanced Malignancies
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia
Cystic Fibrosis
Primary: Accuracy of CO2 Levels — 48.9; 39.5; 41.5; 44.3 mmHg
N/A N=20 Radiological Evaluation of Radiesse Implantation in the Hands
Volume Loss in the Dorsum of the Hand
Primary: Number of Participants With X-ray of Either Hand With Bone Obscuration at Month 1 — 0; 0 participants
N/A N=60 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 98.3 percentage of participants
Phase 2 N=47 Neem Lotion With Combing for Lice
Pediculoses · Head Lice
Primary: Number of Participants Free From Head Louse Infestation as Assessed by Detection Combing — 23; 22 Participants
Phase 3 N=309 A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Hypercholesterolemia · Heterozygous Familial
Primary: Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1 — -27.17; -6.77; -22.96; -10.62 Percent
Phase 4 N=71 Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) — 5; 51 Participants
Phase 4 N=143 Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) — 7; 7; 57; 69 Participants
Phase 1 N=60 Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t)) — 1330; 1340; 1020; 1500 hr·ng/mL
Phase 3 N=130 Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
Lung Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months — 64.5; 54.6 mL/min — p=<0.0001
Phase 3 N=1,337 12-Week Study of Plecanatide for CIC (The National CIC3 Study)
Chronic Idiopathic Constipation
Primary: Number of Durable Overall CSBM Responders, Mean Replacement Approach — 57; 88; 88 Participants
Phase 2 N=8 Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
Aging
Primary: Change in Microbiome — 0; 0; 0 Operational Taxonomic Unit (OTU)
N/A N=120 Financial Incentives to Exercise for Adolescents
Insulin Resistance · Obesity · Sedentary Lifestyle
Primary: Change From Baseline in Volume of Exercise (Total Time) — 15.2; 15.0; 8.0; 12.4 hours
N/A N=100 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
Rheumatoid Arthritis
Primary: Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24 — -0.44 units on a scale — p=<0.0001
Phase 4 N=57 Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study
Shock
Primary: Patient Accrual Rate Over One Year (% of Target Sample Size Achieved) — 82 percentage of target sample size